News & Videos - CROSSJECT - English

Dijon, France April 2, 2024 – Trading of the stock of Crossject (ISIN: FR0011716265; Euronext: ALCJ) on the Euronext exchange will resume as normal on Wednesday, April 3 at 09:00 CET. Crossject’s press release, entitled “Crossject advances in its U.S. Strategy and reports Financial Results for 2023”, was published at 10:30am CET, due to a delay in receiving certain confirmations. For that reason, Crossject required Euronext to stop trading. Following Euronext’s standard procedure in...

Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDA Expectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE® in Q1 2025 Expectation to complete U.S. New Drug Application (NDA) for ZEPIZURE® in H1 2025 Reinforcement of supply chain [with addition of a second fill-and-finish CDMO] Reporting of a reduced Net loss of €8.5 million versus €11.2 million in 2022 Dijon, France April 2, 2024, 10:30am CET --...

Dijon, France, March 8, 2024 – 7:30 pm CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, today announces its EU Gender Equality Index score reached 96/100 for 2024, marking the third successive year it has been above 90%. The Gender Equality Index is a tool to measure the progress of gender equality in the EU, giving more visibility to areas that need improvement and ultimately supporting policy...

Dijon, February 27, 2024 at 8:30am Crossject obtains a financing up to €12 million, in two tranches, from an entity managed by Heights Capital Management, in issued bonds convertible in new shares, with a conversion premium of 35% 1 , or repayable (in cash and/or stocks, according to the company’s options) over 36 months at a rate of 7% 2 . CROSSJECT (ISIN: FR0011716265; Stock symbol: ALCJ) , a specialty pharma company developing needle-free auto-injectors for emergency situations, ,...

Dijon, France, February 1, 2024 -- 18:15 CET - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, will hold a conference call on its commercial strategy in the U.S. and Europe on February 6, 2024 at 17:30 CET. The presentation will be held in English. Patrick Alexandre, Crossject’s CEO and Executive Chairman, and Olivier Gire, COO of Specialty Pharma, will provide a business update following the January 4...

Press Release Crossject to present at Biotech Showcase on January 9 at 16:30 PT Dijon, France, January 9, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, will hold a presentation at the Biotech Showcase conference, being held in San Francisco, on January 9, 2024 at 16:30 PT (January 10, 01:30 CET). Details of the presentation: Time: Tuesday, January 9, 2024, 16:30 PT Track: Yosemite C (Ballroom...

Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE ®  Crossject expanding market access activities in preparation for filing for marketing authorization ZEPIZURE ® , previously known as ZENEO ® Midazolam, is separately contracted with BARDA for U.S. advanced regulatory development and specific supply to the Strategic National Stockpile Dijon, France, January 4, 2024, 18:00 CET -- Crossject (ISIN: FR0011716265; uronext: ALCJ), a specialty pharma company...

Crossject to receive up to €1 million on marketing approvals, plus a markup on sales linked to gross margin Agreement, with undisclosed strategic partner, allows Crossject to benefit from strong expertise in the field and provides impetus to commercial launches Dijon, France 22 December, 2023, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, announces it has concluded a commercialization...

Press Release Crossject reports successful completion of European and U.S. audits for manufacturing of ZENEO ® Midazolam for epilep tic seizure s ISO 13485 certification renewed for manufacturing sites at Gray and Dijon French Health Agency upgrades GMP certification to commercial use U.S. audit readiness of Crossject Dijon and Gray manufacturing sites for a potential FDA audit Dijon, France , September 5, 2023 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company...

Press Release Crossject signs n ew licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand  Exclusive licensing, distribution and promotion agreement for ZENEO® Midazolam in epileptic seizures in Australia and New Zealand Pre-marketing payments of about €0.5m due to Crossject from AFT Dijon, France 20 July 2023 -- Crossject (ISIN: FR0011716265; Euronext : ALCJ), a specialty pharma company that develops and will soon market a...

Press Release Crossject signs n ew licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand  Exclusive licensing, distribution and promotion agreement for ZENEO® Midazolam in epileptic seizures in Australia and New Zealand Pre-marketing payments of about €0.5m due to Crossject from AFT Dijon, France 20 July 2023 -- Crossject (ISIN: FR0011716265; Euronext : ALCJ), a specialty pharma company that develops and will soon market a...

Press release Dijon, 1 st June 2023, 6.30 p.m. Appointment of Daniel Teper to the Crossject Supervisory Board Building skills to support the US transition CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of drugs for use in emergency situations (epilepsy, allergic shock, overdose, asthma attack, adrenal insufficiency, etc.), has decided to submit Daniel Teper’s appointment as a Director on its Supervisory Board...

Press release CLINICAL DEMONSTRATION OF ZENEO® EFFICIENCY FOR INTRAMUSCULAR INJECTION OF MIDAZOLAM • Primary endpoints met and r esults in line with expectations • No impact of clothing on the intramuscular injection with ZENEO® Dijon, November 2, 2022 at 8am CROSSJECT (ISIN: FR0011716265; Mnémo : ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of drug / device combinations for use in emergency situations, is releasing positive headline results...

Press Release Agreement with BARDA on ZENEO ® M idazolam BARDA places a firm order of $60m to CROSSJECT for initial procurement of ZENEO ® Midazolam into the U.S. Strategic National Stockpile 1 as soon as FDA Authorization is obtained BARDA also financially supports the U.S. late-stage development and regulatory activities necessary to obtain FDA approval of ZENEO ® Midazolam 10mg and a new pediatric dose ZENEO ® Midazolam auto injector BARDA has the option to procure additional ZENEO ®...

Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 31 mai 2021 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALC J), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence , publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions...

Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 18 février 2020 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence , publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions...

Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 29 janvier 2020 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence , publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions...

Press release Crossject announces its financial calendar 2018 Dijon, 1st March 2018 CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing a portfolio of innovative combined drugs for use in emergency situations, announces its projected financial calendar 2018. Financial calendar 2018 20 March 2018 * : Annual results 2017 16 May 2018 * : Business update 17 May 2018 : 2018 Annual General Meeting 26 September 2018 * : Interim 2018 results 7 December 2018 * : Business...